Mobile

A multi-center, double-blind, randomized, placebo-controlled dose-ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabetes...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002908-42

A multi-center, double-blind, randomized, placebo-controlled dose-ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabetes mellitus treated with a stable dose of metformin

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the BID dose(s) of RO4389620 administered in combination with metformin, which when compared to placebo (metformin monotherapy) are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens